Literature DB >> 3324470

Immunologic reconstitution of foals with combined immunodeficiency.

L E Perryman1, C M Bue, N S Magnuson, V D Mottironi, H S Ochs, C R Wyatt.   

Abstract

Thirty-eight foals with combined immunodeficiency (CID) received transplanted fetal liver cells, fetal liver and thymus cells, histocompatible bone marrow cells, or equine lymphocyte antigen (ELA) haploidentical bone marrow cells in an attempt to reconstitute their deficient immune systems. Engraftment was infrequent, partial, and unpredictable when fetal cells were employed. Three of five CID foals receiving ELA haploidentical bone marrow cells demonstrated partial reconstitution, but engraftment was only temporary. Administration of histocompatible bone marrow cells resulted in rapid, full and sustained engraftment.

Entities:  

Mesh:

Year:  1987        PMID: 3324470     DOI: 10.1016/0165-2427(87)90165-6

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  4 in total

1.  Three monoclonal antibodies identifying antigens on all equine T lymphocytes, and two mutually exclusive T-lymphocyte subsets.

Authors:  D P Lunn; M A Holmes; W P Duffus
Journal:  Immunology       Date:  1991-10       Impact factor: 7.397

2.  Immune reconstitution prevents continuous equine infectious anemia virus replication in an Arabian foal with severe combined immunodeficiency: lessons for control of lentiviruses.

Authors:  R H Mealey; D G Fraser; J L Oaks; G H Cantor; T C McGuire
Journal:  Clin Immunol       Date:  2001-11       Impact factor: 3.969

3.  Abnormal patterns of equine leucocyte differentiation antigen expression in severe combined immunodeficiency foals suggests the phenotype of normal equine natural killer cells.

Authors:  D P Lunn; J T McClure; C S Schobert; M A Holmes
Journal:  Immunology       Date:  1995-03       Impact factor: 7.397

4.  Combined immunodeficiency in 3 foals.

Authors:  J T McCLURE; D P Lunn; S M McGUIRK
Journal:  Equine Vet Educ       Date:  2010-04-26       Impact factor: 1.063

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.